CXCR4 and neoplasm: The findings of this in-vivo and in-vitro study suggest the potential efficacy of combining AMD3100 with cisplatin for treating OSCC in cases where the tumor-suppressive effect of cisplatin alone is limited. The amalgamation of cisplatin and a CXCR4 inhibitor may provide a promising novel approach for managing refractory OSCC.